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Pseudomonas and Bacillus Soil Isolates Produce Antibiotics
Chelsea Brandt and Dr. Lori Scott
METHODS
Unless described otherwise, the bacterial strains and protocols used 
in this study were provided by the Tiny Earth Project Initiative 
(TEPI) [5].
• Soil samples were collected from Duck Creek Park in Davenport, 
IA on January 9, 2020.
• Using a slurry of the soil sample, serial dilutions were made and 
then plated onto LB agar, 10% TSA, and PDA petri dishes and 
cultured at 28ºC for 48 hours.
• Bacteria colonies were streaked and cultured on master plates of 
corresponding media.  
• Bacteria from the master plates were streaked onto spread plates 
of Bacillus subtilis and Escherichia coli to observe any zones of 
inhibition.
• Colony PCR was run on confirmed antibiotic producers. DNA 
from gel electrophoresis was extracted and analyzed by 16S 
rRNA genetic sequencing at the Iowa Institute of Human 
Genetics at the University of Iowa using the primers 27F and 
1492R. 
• NCBI BLAST was used to identify the genus of the antibiotic 
producing soil isolates. 
DISCUSSION
Antibiotic producing bacteria were isolated from an Iowa soil 
sample and identified as Bacillus and Pseudomonas, which are both 
consistent with common bacteria found in soil [1, 3]. Data from this 
project was sent to TEPI to be recorded in the national database and 
used for further research. In future studies, the bioactive molecule 
produced by the samples should be identified and isolated using a 
biological assay and chemical techniques for isolation and 
purification [5]. The identity of the molecules should be compared 
with known antibiotics to determine whether a novel antibiotic was 
produced and can be developed into new antibiotics. Additionally, 
CB-18-TSA should be taken through the processes of16S rRNA 
gene sequencing and identification of bioactive molecules as it was 
also a confirmed antibiotic producer. 
Figure 1 
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RESULTS
Figure 3. Gel electrophoresis of CB-7-LB (lanes 2&3) and CB-7-
TSA (lanes 4&5) shows discrete DNA bands at approximately 1.5 
Kb. The electrophoresis was performed in a 1% agarose gel run at 
100V for thirty minutes. The lanes are as follows: 1: molecular 
weight ladder, 2&3: CB-7-LB and 4&5: CB-7-TSA. The DNA from 
these bands were excised and purified to be sent to the University of 
Iowa for 16S rRNA genetic sequencing.  
RESULTS (CONTINUED)
Figure 4. NCBI BLAST results show that CB-7-LB is of the genus 
is Bacillus and CB-7-TSA is of the genus Pseudomonas [3]. Query 
coverage indicates the percentage of the gene that was sequenced in 
the database. The percent identity indicates the percentage of base 
pairs from the experimental sample that are identical to the hit from 
the database. The E value indicates the probability that the hits 
would have been pulled out of the database at random. Both 
samples show a query coverage at 99%, percent identity above 99%, 
and E values at zero which indicates the validity of these results. 
For both samples, the genus shows no variability in the top ten hits 
while the species varies without significant differences in the 
statistical values. Therefore, the identity of the genus can be 
confirmed while the species cannot be and it is concluded that CB-
7-LB is Bacillus and CB-7-TSA is Pseudomonas.
Figure 2. Soil isolates CB-7-
TSA, CB-7-LB, and CB-11-
LB are confirmed to produce 
antibiotics. Each of these 
isolates exhibit a zone of 
inhibition (ZOI) against B. 
subtilis. Only CB-7-LB 
exhibits a ZOI against E. 
coli. CB-7-LB and CB-7-
TSA show the largest ZOIs 
so these two isolates were 
chosen to undergo further 
genetic testing for 
identification.  
INTRODUCTION
Antibiotics have been a prominent tool for treating infection for 
nearly 100 years, but the recent emergence of antibiotic resistant 
strains of bacteria have prompted scientific inquiry into new 
methods of fighting infection [8]. With the list of effective 
medications diminishing and the limited discovery of new 
antibiotics, antibiotic resistance poses a significant threat to 
human survival [8]. Of particular importance to the discussion of 
antibiotic resistance are the ESKAPE pathogens: Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter spp. These pathogens cause 15.5% of nosocomial 
infections worldwide, are associated with high risks of mortality, 
and are becoming increasingly resistant to existing medications, 
making them one of the most important groups of bacteria to 
study [2, 6, 9, 10]. While studies of combinations of antibiotics, 
bacteriophage therapy, antimicrobial peptides, photodynamic light 
therapy, and silver nanoparticles show potential, the discovery of 
new antibiotics remains crucial for combating antibiotic 
resistance [8]. The Tiny Earth Project Initiative (TEPI) is one 
such global, student oriented research project that confronts the 
antibiotic resistance crisis by searching for new antibiotics in soil 
samples [5].
On a global level, TEPI aims to educate students and 
professionals about the antibiotic crisis while amassing soil 
bacteria data and isolating novel antibiotic producers [5]. This 
poster details an experiment that contributes to TEPI by isolating 
antibiotic producing bacteria in a local Iowa soil sample. Soil 
bacterial isolates are tested against known tester strains Bacillus 
subtilis and Escherichia coli. B. subtilis is a fast growing, Gram 
positive, rod shaped bacteria typically found in soil, water, and 
around plants [7]. It is extensively studied and valued for its 
protein production abilities [7]. E. coli is a fast growing, Gram 
negative, rod shaped bacteria typically found in the 
gastrointestinal tract of humans and animals. Most strains of E. 
coli are harmless, but some strains have acquired pathogenicity 
and are a common foodborne pathogen [11]. By testing unknown 
soil isolates against B. subtilis and E. coli, student researchers 
eliminate the risk of exposure to the dangerous antibiotic resistant 
ESKAPE strains while still permitting inquiry into new methods 
of treatment. With antibiotic resistance spreading so quickly 
between bacterial species, the human population is in dire need of 
research into new antibiotics. By contributing to TEPI, this 
project increases the range of potential antibiotic producing 
bacteria and promotes further research into novel antibiotics to 
combat antibiotic resistance. 
Figure 1. CDC data from 2013 shows a decreasing number of 
FDA approvals of new antibiotics since the 1980s [4].  
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